Bibliographic information
Recommendation
Initiation of Progestogen-only injectable contraceptives (POIs). Switching from an IUD (including the LNG-IUD) • Within 7 days of the start of menstrual bleeding: The first injection can be given. No additional contraceptive protection is needed. The IUD can be removed at that time. • More than 7 days after the start of menstrual bleeding: The first injection can be given if it is reasonably certain that the woman is not pregnant. ‒ If the woman has been sexually active in this menstrual cycle and it is more than 7 days since the start of menstrual bleeding: It is recommended that the IUD be removed at the time of her next menstrual period.‒ If the woman has not been sexually active in this menstrual cycle and it is more than 7 days since the start of menstrual bleeding: She will need to abstain from sex or use additional contraceptive protection for the next 7 days. If that additional protection is to be provided by the IUD she is using, it is recommended that this IUD be removed at the time of her next menstrual period. • If the woman is amenorrhoeic or has irregular bleeding, she can have the injection as advised for other amenorrhoeic women
Recommended in favor
Strong
Notes and Remarks
The GDG considered that an injection given up to Day 7 of the menstrual cycle results in a low risk of an ovulatory cycle that could lead to pregnancy. The need for additional contraceptive protection among those switching from another hormonal method will depend on the previous method used. In the context of switching from an IUD to an injectable, there was some concern about the risk of pregnancy when removing an IUD within a cycle where there has already been intercourse. That concern led to the recommendation that the IUD be left in place until the next menstrual period. Whereas an estimated 48 hours of POP use was deemed necessary to achieve a contraceptive effect on cervical mucus, the time required for POIs to exert such an effect was uncertain. In their review of the evidence, the GDG noted that DMPA-SC efficacy is maintained when administered in the upper arm, which may be acceptable to women in addition to subcutaneous injection in the abdomen or thigh.
Also Featured In
This recommendation also appears in the following guidelines:
Selected practice recommendations for contraceptive use